Drugs / L-fucose
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03354533 | Jan 2012 → Nov 2018 | leukocyte adhesion deficiency type II | Orpha Labs | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT07432490 Comparator | May 2026 → Jul 2027 expected | GLUT1 deficiency syndrome | Oregon Health and Science University | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | L-fucose | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03354533 ↗ |
| Known as | ORL-1F | “Treatment with ORL-1F - L-fucose” NCT03354533 ↗ |
| Route | Oral | “by mouth” NCT07432490 ↗ |